Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Retinoblastoma

Retinoblastoma is the most common intraocular malignancy of childhood [S9]. Outcomes depend heavily on where a child lives: survival and globe salvage correlate with national income level, and delayed presentation with advanced disease is common in low- and middle-income countries (LMICs) [S6] [S9].

Key points - Early detection matters: prolonged time to diagnosis is associated with more extraocular disease and higher mortality [S2]. - The red reflex is the most widely used screening technique, and universal newborn eye screening is recommended by one systematic review [S5]. - Enucleation is curative for intraocular disease; treatment intensity should match the resources available [S1]. - Globe-salvage options (systemic chemotherapy with focal consolidation, intra-arterial and intravitreal chemotherapy) are limited in LMICs by availability and cost [S9]. - Children with heritable retinoblastoma carry a markedly increased lifelong risk of second primary cancers [S8].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags

• Delay in diagnosis. In Latin America the median time from first symptom to diagnosis ranged from 3 to 5 months, and prolonged delay was associated with more extraocular disease and mortality [S2].
• Late, extraocular disease. In developing countries retinoblastoma is often diagnosed after it has spread beyond the eye [S1].
• Heritable disease. Approximately 45% of patients with retinoblastoma carry a germline RB1 pathogenic variant and are at risk of pineal trilateral retinoblastoma [S3].
• Abandonment of treatment. Poor treatment compliance is a major obstacle to cure in developing countries [S1].

Recognise it

• An altered red reflex is the basis of most screening devices and mobile phone applications now used in community screening [S5].
• Median age at diagnosis in Latin American series ranged from 16.5 to 22.2 months [S2].
• Survival gaps are largest in sub-Saharan Africa and southeast and southwest Asia [S6].

Confirm it

• Staging and treatment recommendations for unilateral and bilateral disease in developing countries are set out in the SIOP-PODC guideline, which uses a classification based on locally available resources [S1].
• Examination under anaesthesia and ultrasonography were used to assess eyes at diagnosis and after chemotherapy in an Indian RCT [S7].
• Pineal trilateral retinoblastoma: of 22 asymptomatic patients, 21 (95%) were diagnosed before 40 months of age, with a lead time of about 1 year from asymptomatic to symptomatic disease [S3]. Six-monthly MRI from diagnosis of heritable disease until 36 months of age would need at least 311 scans to detect one asymptomatic case (low-level GRADE evidence) [S3].

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

• Check the red reflex in newborns and infants; red reflex testing is the most widely employed screening technique [S5].
• Health-worker training and public awareness campaigns in LMICs have been followed by less extraocular spread and less treatment refusal or abandonment in pre-post studies, though all were at serious risk of bias [S4].
• Counsel families early about the importance of completing treatment [S1].

Tier B (general eye clinic)

• Confirm suspicion and refer to a centre that treats retinoblastoma (see Refer when).
• Enucleation is curative for intraocular disease, which matters where globe-salvage services are out of reach [S1].

Tier C (specialist centre)

1. Graduated intensity. SIOP-PODC recommendations adapt staging and treatment to available resources and address counselling of families for whom compliance is an issue [S1].
2. Conservative treatment of advanced intraocular disease. Systemic chemotherapy with focal consolidation, intra-arterial chemotherapy (IAC) and intravitreal chemotherapy allow globe salvage, but cost, long treatment duration, repeated examinations under anaesthesia, side effects and the risk of failure must be discussed with parents [S9]. External beam radiotherapy remains useful for recalcitrant disease despite the risk of second cancers in germline carriers [S9].
3. IAC versus intravenous chemotherapy (IVC). A 2026 Cochrane review found that IAC probably increases overall globe salvage compared with IVC (HR 2.01; 1 RCT, 143 eyes; moderate certainty), with probably little or no difference in overall survival [S12]. Adding IVC to IAC may make little or no difference to globe salvage (low certainty, non-randomised studies) [S12].
4. Higher-dose carboplatin. In a single-centre RCT of 32 group D and E eyes in India, higher-dose carboplatin-based IVC did not improve globe or vision salvage over standard dosing [S7]. Doses as reported in [S7]: standard versus higher dose carboplatin of 18.6 vs 28 mg/kg (under 36 months) or 560 vs 840 mg/m² (36 months and older), with vincristine and etoposide.
5. Intravitreal chemotherapy. A single-arm meta-analysis of 1082 eyes reported an overall enucleation rate of 24.70% [S11]. Pigmentary retinopathy occurred in 36.56% of eyes with melphalan versus 2.42% with topotecan; nearly all studies had serious risk of bias [S11].
6. Adjuvant chemotherapy after enucleation. In an RCT of 187 children with unilateral retinoblastoma and high-risk pathology, 3 cycles of CEV (carboplatin, etoposide, vincristine) gave 5-year disease-free survival of 90.4% versus 89.2% with 6 cycles, meeting non-inferiority, with fewer adverse events and lower cost [S10].
7. Survivorship. Hereditary retinoblastoma carries a pooled standardised incidence ratio for second primary cancers of 17.55, versus 1.36 (not significant) for non-hereditary disease; chemotherapy and radiotherapy were associated with increased risk in hereditary patients [S8].

Refer when

Pitfalls

• Assuming a delay of a few months is harmless: prolonged time to diagnosis is associated with worse outcomes [S2].
• Offering prolonged globe-salvage treatment without discussing cost, duration and failure risk with parents [S9].
• Treating hereditary and non-hereditary survivors alike: second cancer risk differs greatly [S8].
• Over-reading the IAC evidence: only one RCT compared IAC with IVC [S12].

Evidence notes

• Most comparative evidence on chemotherapy routes is non-randomised and at high risk of bias [S11] [S12].
• The small dose RCT [S7] was underpowered to exclude a difference.
• The adjuvant chemotherapy RCT was done in China and applies to unilateral enucleated eyes with high-risk pathology [S10].
• Funding: [S6] was funded by the Health and Medical Research Fund (Hong Kong) and Children Cancer's Foundation (Hong Kong).
• Not covered by these sources: clinical signs other than the red reflex, criteria for secondary enucleation, the details of the International Intraocular Retinoblastoma Classification, genetic testing pathways, chemotherapy dosing outside [S7], and evidence-based referral timings.

Related articles

• The white pupil (leukocoria): urgent assessment
• Ocular ultrasound and point-of-care ultrasound

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.